Karo Pharma’s project portfolio consists of three projects in early development and two product development projekts in the late phase. The early projects are focused on nuclear receptors as target proteins for the development of new drugs. Since year-end 2014/2015, Pfizer develops the project toward the market.  The intention regarding the projects Multiple Sclerosis and Cancer is to find partners for further development.